ARS Pharmaceuticals Inc
NASDAQ:SPRY

Watchlist Manager
ARS Pharmaceuticals Inc Logo
ARS Pharmaceuticals Inc
NASDAQ:SPRY
Watchlist
Price: 13.77 USD -5.94% Market Closed
Market Cap: 1.4B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+10%
Revenue
Forecast
+7%
Operating Income
Forecast
+9%
Net Income
Forecast
+15%

Wall Street
Price Targets

SPRY Price Targets Summary
ARS Pharmaceuticals Inc

Wall Street analysts forecast SPRY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SPRY is 32.23 USD with a low forecast of 26.26 USD and a high forecast of 42 USD.

SPRY Lowest Forecast
Wall Street Target
26.26 USD
91% Upside
SPRY Average Forecast
Wall Street Target
32.23 USD
134% Upside
SPRY Highest Forecast
Wall Street Target
42 USD
205% Upside
Lowest
Price Target
26.26 USD
91% Upside
Average
Price Target
32.23 USD
134% Upside
Highest
Price Target
42 USD
205% Upside
ARS Pharmaceuticals Inc Competitors:
Price Targets
068270
Celltrion Inc
54% Upside
M
MAAT
Maat Pharma SA
213% Upside
CUV
Clinuvel Pharmaceuticals Ltd
140% Upside
E
206650
EuBiologics Co Ltd
33% Upside
068270
Celltrion Inc
54% Upside
M
MAAT
Maat Pharma SA
213% Upside
CUV
Clinuvel Pharmaceuticals Ltd
140% Upside
E
206650
EuBiologics Co Ltd
33% Upside
EXAS
Exact Sciences Corp
51% Upside
CMRX
Chimerix Inc
2% Upside

Revenue
Forecast

Revenue Estimate
ARS Pharmaceuticals Inc

The compound annual growth rate of ARS Pharmaceuticals Inc's revenue for the next 3 years is 57%.

N/A
Past Growth
57%
Estimated Growth
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
ARS Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-11%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
ARS Pharmaceuticals Inc

The compound annual growth rate of ARS Pharmaceuticals Inc's net income for the next 3 years is 44%.

N/A
Past Growth
44%
Estimated Growth
Estimates Accuracy
-70%
Average Miss
What are analyst estimates?

See Also

Summary
SPRY intrinsic value, competitors valuation, and company profile.
DCF Valuation
SPRY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SPRY stock valuation using valuation multiples.
Wall Street Estimates
SPRY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SPRY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SPRY's stock price target?
Price Target
32.23 USD

According to Wall Street analysts, the average 1-year price target for SPRY is 32.23 USD with a low forecast of 26.26 USD and a high forecast of 42 USD.

What is ARS Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
57%

The compound annual growth rate of ARS Pharmaceuticals Inc's revenue for the next 3 years is 57%.

What is ARS Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
44%

The compound annual growth rate of ARS Pharmaceuticals Inc's net income for the next 3 years is 44%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 249,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.